Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation

Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation

To obtain long-term data on the use of everolimus in patients who underwent liver transplantation for hepatocellular carcinoma, we conducted a retrospective, single-center analysis of adult recipients transplanted between 2013 and 2021. Patients on everolimus-incorporating immunosuppression were mat...

Full description

Bibliographic Details
Main Authors: Paolo De Simone, Arianna Precisi, Quirino Lai, Juri Ducci, Daniela Campani, Piero Marchetti, Stefano Gitto
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Cancers
Subjects:
liver transplantation
immunosuppression
everolimus
hepatocellular carcinoma
recurrence
Online Access:https://www.mdpi.com/2072-6694/16/7/1243

Internet

https://www.mdpi.com/2072-6694/16/7/1243

Similar Items